Inventiv Health — Q3 2015 Earnings Presentation
16 slides from Inventiv Health's earnings presentation, Nov 13, 2015
Slide 1: inVentiv Health Third Quarter 2015 Earnings Presentation
inVentiv Health Third Quarter 2015 Earnings Presentation November 16, 2015 Exhibit 99.1 Exhibit 99.1
Slide 2: Forward-Looking Statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current
Slide 3: Quarterly Highlights
Quarterly Highlights Record financial performance in Q3 builds on recent momentum Organic net revenue(1) growth of 16% (13% reported net revenue growth) to $521mm Adjusted EBITDA(2) growth of 44% to $76mm Year-to-date organic revenue(1) and Adjusted EBITDA(2) growth of 13% and 32%, respectively Macr
Slide 4: Clinical Update
Clinical Update Organic net revenue(1) growth of 18% (13% reported net revenue growth) Adjusted EBITDA(2) growth of 54% Backlog conversion accelerating on full service projects Growth is strongest in full service space Strategic resourcing business revenue continues to grow sequentially Miami clinic
Slide 5: Commercial Update
Commercial Update Continued momentum in Q3 Organic net revenue(1) growth of 14% (12% reported net revenue growth) Adjusted EBITDA(2) growth of 35% Selling solutions and communications business strength continues Investing in growth areas within consulting Client interest in Commercial Contract Organ
Slide 6: Consolidated inVentiv Health Q3 2015 Financial Update
Consolidated inVentiv Health Q3 2015 Financial Update The sum of the segments do not reconcile to Consolidated inVentiv Health due to the elimination of intersegment revenue which totaled approximately $2 million for the three months ended 9/30/2015, approximately $9 million for the nine months ende
Slide 7: Clinical Performance
Clinical Performance Net Revenues(1) ($ millions) Adjusted EBITDA(2) ($ millions) The sum of the segments do not reconcile to Consolidated inVentiv Health due to the elimination of intersegment revenue which totaled approximately $2 million for the three months ended 9/30/2015, approximately $9 mill
Slide 8: Clinical Backlog
Clinical Backlog Net Book-to-Bill = Net New Wins / Revenue Earned. Total Clinical Serviceable Backlog Q3 2015 LTM ($ millions) Beginning Backlog $1,942 $1,938 + Net New Wins $285 $963 - Revenue Earned ($245) ($919) Ending Backlog $1,982 $1,982 Net Book-to-Bill (1) 1.16x 1.05x
Slide 9: Commercial Performance
Commercial Performance Net Revenues(1) ($ millions) Adjusted EBITDA(2) ($ millions) The sum of the segments do not reconcile to Consolidated inVentiv Health due to the elimination of intersegment revenue which totaled approximately $2 million for the three months ended 9/30/2015, approximately $9 mi
Slide 10: Appendix
Appendix a iventiv > 10 ©2015 AIIRights Reserved | CONFIDENTIAL Health
Slide 11: EBITDA Reconciliation: Quarter and Last Nine Months Ended September 30
For the Quarter and Last Nine Months Ended September 30, 2015 ($ millions) Adjusted EBITDA Reconciliation Note: Please refer to slide 16 for footnotes.
Slide 12: EBITDA Reconciliation: Quarter Ended September 30, 2015
For the Quarter Ended September 30, 2015 ($ millions) Adjusted EBITDA Reconciliation Note: Please refer to slide 16 for footnotes.
Slide 13: EBITDA Reconciliation: Quarter Ended September 30, 2014
For the Quarter Ended September 30, 2014 ($ millions) Adjusted EBITDA Reconciliation Note: Please refer to slide 16 for footnotes.
Slide 14: EBITDA Reconciliation: Nine Months Ended September 30, 2015
For the Nine Months Ended September 30, 2015 ($ millions) Adjusted EBITDA Reconciliation Note: Please refer to slide 16 for footnotes.
Slide 15: EBITDA Reconciliation: Nine Months Ended September 30, 2014
For the Nine Months Ended September 30, 2014 ($ millions) Adjusted EBITDA Reconciliation Note: Please refer to slide 16 for footnotes.
Slide 16: Adjusted EBITDA Footnotes
Adjusted EBITDA Footnotes Represents non-cash losses associated with the write-off of goodwill, intangible assets and other long-lived assets that affect the comparability of our operational results and for which an adjustment is made consistent with the terms of our debt instruments. Represents non